<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:55:16Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4266921" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4266921</identifier><datestamp>2014-12-24</datestamp><setSpec>bsr</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Biosci Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Biosci. Rep</journal-id>
      <journal-id journal-id-type="pmc">bsr</journal-id>
      <journal-id journal-id-type="publisher-id">BSR</journal-id>
      <journal-title-group>
        <journal-title>Bioscience Reports</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0144-8463</issn>
      <issn pub-type="epub">1573-4935</issn>
      <publisher>
        <publisher-name>Portland Press Ltd.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4266921</article-id>
      <article-id pub-id-type="pmcid">PMC4266921</article-id>
      <article-id pub-id-type="pmc-uid">4266921</article-id>
      <article-id pub-id-type="pmid">25495645</article-id>
      <article-id pub-id-type="publisher-id">e00160</article-id>
      <article-id pub-id-type="doi">10.1042/BSR20140115</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Paper</subject>
        </subj-group>
        <subj-group subj-group-type="Primary">
          <subject>S4</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation</article-title>
        <alt-title alt-title-type="right-running-head">Silencing of ANGPTL3 in human hepatocytes</alt-title>
        <alt-title alt-title-type="left-running-head">A. Tikka and others</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Tikka</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="A1">*</xref>
          <xref ref-type="corresp" rid="COR1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soronen</surname>
            <given-names>Jarkko</given-names>
          </name>
          <xref ref-type="aff" rid="A1">*</xref>
          <xref ref-type="aff" rid="A2">â </xref>
          <xref ref-type="author-notes" rid="fn1">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Laurila</surname>
            <given-names>Pirkka-Pekka</given-names>
          </name>
          <xref ref-type="aff" rid="A1">*</xref>
          <xref ref-type="author-notes" rid="fn1">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Metso</surname>
            <given-names>Jari</given-names>
          </name>
          <xref ref-type="aff" rid="A1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ehnholm</surname>
            <given-names>Christian</given-names>
          </name>
          <xref ref-type="aff" rid="A1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jauhiainen</surname>
            <given-names>Matti</given-names>
          </name>
          <xref ref-type="aff" rid="A1">*</xref>
        </contrib>
        <aff id="A1">*National Institute for Health and Welfare, Public Health Genomics Unit, Biomedicum, Helsinki, Finland</aff>
        <aff id="A2">â Minerva Foundation Institute for Medical Research, Helsinki, Finland</aff>
      </contrib-group>
      <author-notes>
        <corresp id="COR1"><sup>1</sup>To whom correspondence should be addressed (email <email>anna.tikka@thl.fi</email>).</corresp>
        <fn id="fn1" fn-type="equal">
          <p><sup>2</sup>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>34</volume>
      <issue>6</issue>
      <elocation-id>e00160</elocation-id>
      <history>
        <date date-type="received">
          <day>6</day>
          <month>8</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>5</day>
          <month>11</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>11</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Homozygosity of loss-of-function mutations in <italic>ANGPTL3</italic> (angiopoietin-like protein 3)-gene results in FHBL2 (familial combined hypolipidaemia, OMIM #605019) characterized by the reduction of all major plasma lipoprotein classes, which includes VLDL (very-low-density lipoprotein), LDL (low-density lipoprotein), HDL (high-density lipoprotein) and low circulating NEFAs (non-esterified fatty acids), glucose and insulin levels. Thus complete lack of ANGPTL3 in humans not only affects lipid metabolism, but also affects whole-body insulin and glucose balance. We used wild-type and <italic>ANGPTL3-</italic>silenced IHHs (human immortalized hepatocytes) to investigate the effect of <italic>ANGPTL3</italic> silencing on hepatocyte-specific VLDL secretion and glucose uptake. We demonstrate that both insulin and PPARÎ³ (peroxisome-proliferator-activated receptor Î³) agonist rosiglitazone down-regulate the secretion of ANGPTL3 and TAG (triacylglycerol)-enriched VLDL1-type particles in a dose-dependent manner. Silencing of <italic>ANGPTL3</italic> improved glucose uptake in hepatocytes by 20â50% and influenced down-regulation of gluconeogenic genes, suggesting that silencing of <italic>ANGPTL3</italic> improves insulin sensitivity. We further show that <italic>ANGPTL3</italic>-silenced cells display a more pronounced shift from the secretion of TAG-enriched VLDL1-type particles to secretion of lipid poor VLDL2-type particles during insulin stimulation. These data suggest liver-specific mechanisms involved in the reported insulin-sensitive phenotype of ANGPTL3-deficient humans, featuring lower plasma insulin and glucose levels.</p>
      </abstract>
      <abstract abstract-type="short">
        <p>We show that silencing of ANGPTL3 in human hepatocytes in addition to reducing secretion of TAG-enriched VLDL upon insulin stimulation enhances glucose uptake and improves insulin response. Thus, our data provide insight into the lower insulin and glucose levels observed in humans with ANGPTL3 loss-of-function mutation.</p>
      </abstract>
      <kwd-group kwd-group-type="kwd">
        <kwd>ANGPTL3 silencing</kwd>
        <kwd>hypolipidaemia</kwd>
        <kwd>insulin signalling</kwd>
        <kwd>liver</kwd>
        <kwd>rosiglitazone</kwd>
        <kwd>VLDL</kwd>
      </kwd-group>
      <kwd-group kwd-group-type="abbr">
        <kwd>ANGPTL, angiopoietin-like protein</kwd>
        <kwd>CCD, coiled coil domain</kwd>
        <kwd>FHBL2, familial combined hypolipidaemia</kwd>
        <kwd>GLUT2, glucose transporter 2</kwd>
        <kwd>HDL, high-density lipoprotein</kwd>
        <kwd>IHH, immortalized human hepatocyte</kwd>
        <kwd>IR, insulin receptor</kwd>
        <kwd>IRS, insulin receptor substrate</kwd>
        <kwd>LDL, low-density lipoprotein</kwd>
        <kwd>LPL, lipoprotein lipase</kwd>
        <kwd>NEFA, non-esterified fatty acid</kwd>
        <kwd>PEPCK, phosphoenolpyruvate carboxykinase</kwd>
        <kwd>PGC1Î±, peroxisome proliferator-activated receptor Î³ co-activator 1-Î±</kwd>
        <kwd>PI3K, phosphoinositide 3-kinase</kwd>
        <kwd>PL, phospholipid</kwd>
        <kwd>PPAR, peroxisome-proliferator-activated receptor</kwd>
        <kwd>QPCR, quantitative PCR</kwd>
        <kwd>shRNA, small hairpin RNA</kwd>
        <kwd>TAG, triacylglycerol</kwd>
        <kwd>TRB3, tribbles homologue 3</kwd>
        <kwd>VLDL, very-low-density lipoprotein</kwd>
      </kwd-group>
      <counts>
        <fig-count count="9"/>
        <table-count count="1"/>
        <ref-count count="39"/>
        <page-count count="11"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The ANGPTLs (angiopoietin-like proteins) are a family of secreted proteins which share tertiary structural domains with angiopoietins [<xref rid="B1" ref-type="bibr">1</xref>], with N-terminal CCD (coiled coil domain) and C-terminal FLD (fibrinogen-like domain) of which the CCD is functionally associated with reduced plasma TAGs (triacylglycerols) [<xref rid="B2" ref-type="bibr">2</xref>]. <italic>ANGPTL3</italic> is almost exclusively expressed in the liver with minor expression found in kidney [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>]. ANGPTL3 has been shown to inhibit LPL (lipoprotein lipase) <italic>inÂ vitro</italic> and <italic>inÂ vivo</italic> [<xref rid="B5" ref-type="bibr">5</xref>â<xref rid="B7" ref-type="bibr">7</xref>], and mice lacking ANGPTL3 protein have increased LPL activity and reduced levels of plasma TAG [<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>].</p>
      <p>GWAS (genome wide association studies) in humans have shown that SNPs (single nucleotide polymorphisms) at loci near <italic>ANGPTL3</italic> are associated with plasma TAG levels [<xref rid="B10" ref-type="bibr">10</xref>â<xref rid="B12" ref-type="bibr">12</xref>]. Sequencing of the coding region of <italic>ANGPTL3</italic> revealed additional loss-of-function mutations associated with low levels of plasma TAG [<xref rid="B4" ref-type="bibr">4</xref>]. Furthermore, Musunuru et al. [<xref rid="B13" ref-type="bibr">13</xref>] have identified E128X and S17X as two novel nonsense mutations in <italic>ANGPTL3.</italic> Loss of function in <italic>ANGPTL3</italic> results in a condition referred to as FHBL2 (familial combined hypolipidaemia, OMIM #605019), featuring reduction in all major plasma lipoproteins VLDL (very-low-density lipoprotein), LDL (low-density lipoprotein) and HDL (high-density lipoprotein). In addition to FHBL2 phenotype also plasma NEFAs (non-esterified fatty acids), insulin, fasting plasma glucose and HOMA-IR (homoeostatic model assessment of insulin resistance) values are significantly lower in individuals homozygous for S17X mutation compared with carriers and non-carriers [<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>] linking the hypolipidaemic effect of ANGPTL3-deficiency with insulin sensitivity.</p>
      <p>Insulin is the primary hormone controlling whole body glucose and lipid homoeostasis. Activation of the insulin-signalling pathway suppresses hepatic secretion of TAG-enriched VLDL1 particles without affecting the secretion of lipid-poor VLDL2 [<xref rid="B16" ref-type="bibr">16</xref>]. The number of TAG-enriched VLDL1 particles is elevated during insulin resistance, contributing to hypertriglyceridaemia [<xref rid="B17" ref-type="bibr">17</xref>]. Despite elevated plasma glucose and TAG levels liver persistently continues glucose production and VLDL secretion during IR [<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>]. Insulin inhibits VLDL secretion through PI3K (phosphoinositide 3-kinase)-mediated abruption in the second-step bulky TAG-assembly of VLDL1 particles and apoB-100 availability [<xref rid="B20" ref-type="bibr">20</xref>]. Unlike in the muscle and adipose tissue, insulin does not directly increase glucose uptake in the liver. Postic et al. [<xref rid="B21" ref-type="bibr">21</xref>] demonstrated down-regulation of GLUT2 (glucose transporter 2) by insulin in a dose-dependent manner <italic>inÂ vivo</italic> and <italic>inÂ vitro</italic>. Hepatic GLUT2 expression is induced by high glucose concentration which, during feeding, prevent the inhibitory effect of insulin on GLUT2 expression [<xref rid="B21" ref-type="bibr">21</xref>].</p>
      <p>We utilized wild-type IHHs (immortalized human hepatocytes) and IHH cells with silenced ANGPTL3 to study how the secretion levels of ANGPTL3 are regulated in hepatocytes and how the silencing of <italic>ANGPTL3</italic> affects VLDL secretion and hepatocyte-specific glucose uptake. The aim of the research is to seek further insight into the molecular mechanisms related to hypolipidaemia and insulin sensitivity reported in humans with ANGPTL3 deficiency [<xref rid="B14" ref-type="bibr">14</xref>].</p>
    </sec>
    <sec sec-type="materials|methods">
      <title>MATERIALS AND METHODS</title>
      <sec>
        <title><italic>ANGPTL3</italic>-silenced cell-line and cell culture conditions</title>
        <p>Liver IHHs immortalized by SV40 large T-Antigen (IHH, ATCCÂ® PTA-5565â¢) were transduced with MISSIONâ¢ shRNA (small hairpin RNA) Lentiviral Vector particles (TRCN0000242782, Sigma Aldrich) targeting <italic>ANGPTL3</italic> (NM_014495.2) or with non-target shRNA (SHCOO2, Sigma Aldrich) [MOI (multiplicity of infection) 1]. Positive cells were selected against 5Â Î¼g/ml puromycin for 12Â days. The transduction was repeated once after the first selection. Cells were cultured in Williams medium E (Gibco by Life Technologies, 22551-022) with added 10% (v/v) FBS and glutamine 0.2Â mg/ml and incubated +37Â Â°C. FBS was removed during experiments and total protein from cell lysates was used to normalize the data. Cells were washed with PBS (pHÂ 7.4) and lysed in RIPA buffer. Protein concentration was measured with Bradford protein assay (Bio-Rad). Following compounds were used: insulin (bovine, Sigma-Aldrich), Wortmannin (Sigma-Aldrich), Akt1/2 inhibitor (Sigma-Aldrich), rosiglitazone (Cayman Chemical) and GW9662 (Sigma-Aldrich).</p>
      </sec>
      <sec>
        <title>Enzymatic measurements of TAG and PLs (phospholipids)</title>
        <p>TAGs from media and cell lysates were measured with an enzymatic method (GPO-PAP 1488872 kit; Roche Diagnostics Gmbh). Phospholipids were measured from the cell culture media with an enzymatic method (FS 60080970; Diasys Diagnostics).</p>
      </sec>
      <sec>
        <title>ANGPTL3 and apoB-100 ELISA assays</title>
        <p>Concentration of ANGPTL3 was measured utilizing ELISA assay developed by Robciuc et al. [<xref rid="B22" ref-type="bibr">22</xref>]. ApoB-100 was measured with Human apolipoprotein B ELISA kit (Mabtech) according to instructions provided by the manufacturer.</p>
      </sec>
      <sec>
        <title>Labelled oleic acid and TAG extraction</title>
        <p>Cells were incubated in the presence of 5.5Â mM glucose and 0.5% (w/v) BSA-complexed with 0.375Â mM oleic acid and 0.1Â Î¼Ci [<sup>14</sup>C]-oleic acid (PerkinElmer) for 24Â h. Cells were collected in 1Â ml 2% NaClâPBS buffer. Lipids were extracted by adding 2Â ml of methanol and 1Â ml chloroform and centrifuged (2500 rev/min for 10Â min at room temperature). H<sub>2</sub>O (1Â ml) and chloroform (1Â ml) were added and again centrifuged (2500 rev/min, for 10Â min at room temperature). The upper phase was removed and the lower phase dried under nitrogen and solubilized in 100Â Î¼l of chloroform and applied on a TLC-plate. The TLC-plates were run in a chamber containing (<italic>N</italic>-hexane, diethylether, acetic acid and H<sub>2</sub>O (65/15/1/0.25, v/v). Iodine vapour stained areas containing the TAGs were scraped out from the TLC-plate and radioactivity was measured by liquid scintillation counting (Wallac LS-Beta-Counter).</p>
      </sec>
      <sec>
        <title>Measurement of glucose uptake</title>
        <p>Cells were incubated in the presence of 5.5 or 20Â mM glucose and 1Â Î¼Ci of deoxy-<sc>D</sc>-glucose, 2-[1,2-<sup>3</sup>H (N)] (1 mCi/ml, lot 638084, Perkin Elmer). Radioactivity from cell lysates and media was measured by liquid scintillation counter (Wallac LS-Beta-Counter).</p>
      </sec>
      <sec>
        <title>QPCR (quantitative PCR) analysis</title>
        <p>RNA was extracted with Qiagen RNA purification kit and synthesized with SuperScriptÂ® VILOâ¢ cDNA Synthesis Kit (Life Technologies). Each QPCR contained primers (see <xref ref-type="table" rid="T1">Table 1</xref>) at 300Â nM concentration and 10Â ng of cDNA. The total volume of each reaction was 10Â Î¼l containing SYBRÂ® Green PCR Master Mix (Life Technologies). The QPCR program: 95Â Â°C for 10Â min followed by 45 cycles 95Â Â°C 15Â s, 60Â Â°C 1Â min.</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <title>QPCR-primers</title>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Name, gene name</th>
                <th rowspan="1" colspan="1">Forward</th>
                <th rowspan="1" colspan="1">Reverse</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1"><italic>ACTIN</italic>, <italic>ACTB</italic></td>
                <td rowspan="1" colspan="1">GATGTGGATCAGCAAGCAGGA</td>
                <td rowspan="1" colspan="1">AGCATTTGCGGTGGACGAT</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>ANGPTL3</italic>
                </td>
                <td rowspan="1" colspan="1">CCAGAACACCCAGAAGTAACT</td>
                <td rowspan="1" colspan="1">TCTGTGGGTTCTTGAATACTAGTC</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>ANGPTL4</italic>
                </td>
                <td rowspan="1" colspan="1">GCCTATAGCCTGCAGCTCAC</td>
                <td rowspan="1" colspan="1">CAAGTGGAGAAGGGTACGGA</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>ANGPTL8</italic>, <italic>C19ORF80</italic></td>
                <td rowspan="1" colspan="1">AGGTCTTAAAGGCTCACG</td>
                <td rowspan="1" colspan="1">TTCCATCCAGGCAGATTC</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>DGAT2</italic>
                </td>
                <td rowspan="1" colspan="1">CATCCTCATGTACATATTCTGC</td>
                <td rowspan="1" colspan="1">TGGGAAAGTAGTCTCGAAAG</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>HNF4Î±</italic>, <italic>HNF4A</italic></td>
                <td rowspan="1" colspan="1">AGTACATCCCAGCTTTCTG</td>
                <td rowspan="1" colspan="1">AATGTAGTCATTGCCTAGGAG</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>IL-6</italic>
                </td>
                <td rowspan="1" colspan="1">GGTACATCCTCGACGGCATCT</td>
                <td rowspan="1" colspan="1">GTGCCTCTTTGCTGCTTTCAC</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>IRS-1</italic>
                </td>
                <td rowspan="1" colspan="1">CAGAATGAAGACCTAAATGACC</td>
                <td rowspan="1" colspan="1">ATGCATCGTACCATCTACTG</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>IRS-2</italic>
                </td>
                <td rowspan="1" colspan="1">AAGAGTGAAGATCTGTCTGG</td>
                <td rowspan="1" colspan="1">ATCTAACAGAGTCCACAGATG</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>PEPCK</italic>, <italic>PCK1</italic></td>
                <td rowspan="1" colspan="1">GGGCATCCTCAGGCGGCT</td>
                <td rowspan="1" colspan="1">GATAACCGTCTTGCTTTCGAT</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>PGC1A</italic>, <italic>PPARGC1A</italic></td>
                <td rowspan="1" colspan="1">GCAGACCTAGATTCAAACTC</td>
                <td rowspan="1" colspan="1">CATCCCTCTGTCATCCTC</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>PI3K 85</italic>, <italic>PIK3R1</italic></td>
                <td rowspan="1" colspan="1">AAGAAGACTTGAAGAAGCA</td>
                <td rowspan="1" colspan="1">TCAACCACATCAAGTATTGG</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>PPARALPHA</italic>, <italic>PPARA</italic></td>
                <td rowspan="1" colspan="1">CCTAAAAAGCCTAAGGAAACC</td>
                <td rowspan="1" colspan="1">GATCTCCACAGCAAATGATAG</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>PPAR</italic>Î³, <italic>PPARG</italic></td>
                <td rowspan="1" colspan="1">GATCCAGTGGTTGCAGATTACAA</td>
                <td rowspan="1" colspan="1">GAGGGAGTTGGAAGGCTCTTC</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>PTEN</italic>
                </td>
                <td rowspan="1" colspan="1">GGCTAAGTGAAGATGACAATC</td>
                <td rowspan="1" colspan="1">GTTACTCCCTTTTTGTCTCTG</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>TGH</italic>, <italic>TGH/CES1</italic></td>
                <td rowspan="1" colspan="1">GTCTTTCTGGGCATTCCATT</td>
                <td rowspan="1" colspan="1">CTCTCCACGTCTTGTAGGCA</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>TNFÎ±</italic>, <italic>TNFA</italic></td>
                <td rowspan="1" colspan="1">CCCAGGCAGTCAGATCATCTT</td>
                <td rowspan="1" colspan="1">AGCTGCCCCTGAGCTTGA</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>TRB3</italic>, <italic>TRIB3</italic></td>
                <td rowspan="1" colspan="1">GACCGTGAGAGGAAGAAG</td>
                <td rowspan="1" colspan="1">GAGTATCTCAGGTCCCAC</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec>
        <title>Statistics</title>
        <p>The experiments were conducted in triplicate (<italic>n</italic>=3) and performed using 2â3 separately transduced IHH cell cultures. Results are expressed as meansÂ±S.D. One-way or two-way ANOVA was used to compare the significance between groups followed by GamesâHowell <italic>post hoc</italic> test. The difference between groups was considered statistically significant if <italic>P</italic>&lt;0.05 using GamesâHowell <italic>post hoc</italic> test (*&lt;0.05, **&lt;0.01, ***&lt;0.001).</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>RESULTS</title>
      <p>We first tested insulin response in wild-type IHH cells by incubating the cells in the presence of insulin and measured the secretion rate of VLDL by analysing the cell culture media for TAG, apoB-100 and PLs after 24Â h. Insulin treatment resulted in a dose dependent down-regulation of the secreted TAG, PL (<xref ref-type="fig" rid="F1">Figure 1</xref>a) and apoB-100 (<xref ref-type="fig" rid="F1">Figure 1</xref>b). Insulin in a dose-dependent manner reduced also the secretion of ANGPTL3 (<xref ref-type="fig" rid="F1">Figure 1</xref>c). We calculated a TAG/apoB-100 ratio and demonstrated that insulin stimulation results in a significant reduction of hepatocyte TAG secreted per apoB-100 protein (<xref ref-type="fig" rid="F1">Figure 1</xref>d). These data are in line with reports on insulin mediated down-regulation of TAG-enriched VLDL1 particles without affecting the (lipid-poor) VLDL2 secretion [<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B23" ref-type="bibr">23</xref>].</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <title>The effect of insulin on VLDL and ANGPTL3 secretion</title>
          <p>Wild-type IHH-cells were incubated in 5.5Â mM glucose for 24Â h at variable concentrations of insulin. (<bold>a</bold>) Secretion of TAG and PL during insulin stimulation (Î¼g/mg). (<bold>b</bold>) Secretion of apoB-100 (ng/mg). (<bold>c</bold>) Secretion of ANGPTL3 (ng/mg). (<bold>d</bold>) The amount of TAG (ng) for each ng of apoB-100.</p>
        </caption>
        <graphic xlink:href="bsr2014-0115i001"/>
      </fig>
      <p>Insulin mediates its functions via IRS (insulin receptor substrate)âPI3K-dependent pathway [<xref rid="B24" ref-type="bibr">24</xref>]. To test whether VLDL secretion in IHH cells is regulated via PI3K and its downstream target Akt, we incubated cells with a PI3K inhibitor Wortmannin and Akt1/2 inhibitor. Treatment with Wortmannin partly abolished the inhibitory effect of insulin on TAG and PL secretion (<xref ref-type="fig" rid="F2">Figure 2</xref>a). Akt1/2 inhibitor, much like Wortmannin, partially abolished the inhibitory effect of insulin on TAG secretion indicating that insulin regulates the secretion of VLDL via PI3KâAkt pathway in IHH cells (<xref ref-type="fig" rid="F2">Figure 2</xref>b). Wortmannin or Akt1/2 did not abolish the inhibitory effect of insulin on ANGPTL3 secretion suggesting that secretion of ANGPTL3 is not down-regulated via PI3K or Akt (<xref ref-type="fig" rid="F2">Figures 2</xref>c and <xref ref-type="fig" rid="F2">2</xref>d).</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <title>The effect of PI3K Wortmannin, Akt-specific inhibitor Akt1/2 and PPARÎ³ antagonist GW9662 on VLDL and ANGPTL3 secretion</title>
          <p>Wild-type IHH-cells were incubated in 5.5Â mM glucose and 100Â nM insulin (â/+), Wortmannin (0.5Â Î¼M,10Â Î¼M), Akt1/2 inhibitor (20Â Î¼M) or PPARÎ³ antagonist GW9662 (10Â Î¼M) for 24Â h. (<bold>a</bold>) Secretion of TAG and PL (Î¼g/mg). (<bold>b</bold>) Secretion of TAG (Î¼g/mg). (<bold>c</bold>) Secretion of ANGPTL3 (ng/mg). (<bold>d</bold>) Secretion of ANGPTL3 (ng/mg).</p>
        </caption>
        <graphic xlink:href="bsr2014-0115i002"/>
      </fig>
      <p>Since ANGPTL3 protein secretion is regulated by insulin, we investigated whether nuclear PPARs (peroxisome proliferator-activated receptors) Î± and Î³ and their agonists fenofibrate, used to treat high plasma TAG and cholesterol levels, and rosiglitazone, an insulin sensitizer, would affect the secretion of ANGPTL3. We demonstrate that PPARÎ³ agonist rosiglitazone, in a dose-dependent manner, down-regulated mRNA expression (<xref ref-type="fig" rid="F3">Figure 3</xref>a) and the secretion of ANGPTL3 (<xref ref-type="fig" rid="F3">Figure 3</xref>b). PPARÎ± agonist fenofibrate did not affect the secretion of ANGPTL3 (results not shown). Rosiglitazone, much like insulin, reduced the secretion of TAG in a dose-dependent manner (<xref ref-type="fig" rid="F3">Figure 3</xref>c). PPARÎ³ antagonist (GW9662) abolished the inhibitory effect of insulin on TAG secretion (<xref ref-type="fig" rid="F2">Figure 2</xref>b). These data demonstrate that rosiglitazone mimics insulin action in cultured human hepatocytes by decreasing the secretion of TAG and ANGPTL3 in a dose-dependent manner. These data also support the hypothesis that insulin may down-regulate VLDL secretion via PPARÎ³. However, PPARÎ³-antagonist (GW9662) did not abolish the inhibitory effect of insulin on ANGPTL3 secretion (<xref ref-type="fig" rid="F2">Figure 2</xref>d) indicating that insulin and PPARÎ³ down-regulate the expression of ANGPTL3 via different pathways.</p>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <title>The effect of rosiglitazone on VLDL and ANGPTL3 secretion</title>
          <p>Wild-type IHH-cells were incubated in 5.5Â mM glucose and 100Â nM insulin (+/â) for 24Â h following RNA extraction from cell lysates. Secretion of ANGPTL3 PL and TAG was measured in the presence of rosiglitazone. (<bold>a</bold>) Expression of <italic>ANGPTL3</italic> (AU, arbitary unit). (<bold>b</bold>) Secretion of ANGPTL3 (ng/mg). (<bold>c</bold>) Secretion of TAG and PL (Î¼g/mg).</p>
        </caption>
        <graphic xlink:href="bsr2014-0115i003"/>
      </fig>
      <p>To investigate ANGPTL3-specific functions in hepatocytes, we silenced <italic>ANGPTL3</italic>-gene by transducing wild-type IHH cells with a lentiviral vector carrying <italic>ANGPTL3</italic>-targeting shRNA-fragment. Control cells were transduced with non-targeting shRNA. We achieved 85% silencing in <italic>ANGPTL3</italic> expression (<xref ref-type="fig" rid="F4">Figure 4</xref>a) and a 90â95% decrease in ANGPTL3 protein secretion (<xref ref-type="fig" rid="F4">Figure 4</xref>b). We then measured the concentration of TAG, PL and apoB-100 from the cell culture media after 24Â h incubation. Surprisingly the secretion of apoB-100, PL and TAG were all increased in <italic>ANGPTL3</italic>-silenced cells compared with control cells under non-insulin conditions (â) (<xref ref-type="fig" rid="F5">Figures 5</xref>aâ<xref ref-type="fig" rid="F5">5</xref>c). Also a short-term secretion rate of apoB-100 was higher in <italic>ANGPTL3</italic>-silenced cells under non-insulin conditions (<xref ref-type="fig" rid="F5">Figure 5</xref>d). Insulin stimulation (+) reduced the secretion of TAG and PL in silenced cells (<xref ref-type="fig" rid="F5">Figures 5</xref>aâ<xref ref-type="fig" rid="F5">5</xref>b) near to the level of TAG secreted by the control cells with a smaller decrease in secreted apoB-100 levels (<xref ref-type="fig" rid="F5">Figure 5</xref>c). We calculated a TAG/apoB-100 ratio for both control and silenced cells and concluded that the ratio was more dramatically reduced in <italic>ANGPTL3</italic>-silenced cells [47%, from 60 to 32 (mass/mass)] compared with control cells [16%, from 45 to 38 (mass/mass)] during insulin stimulation (+) (<xref ref-type="fig" rid="F5">Figure 5</xref>e). These findings suggest that the silencing of <italic>ANGPTL3</italic> results in a more pronounced shift from the secretion of large TAG-enriched VLDL1-type particles into small lipid-poor VLDL2-type particles during insulin stimulation. These data are in line with plasma measures from ANGPTL3-deficient subjects who had a 4.3-fold reduction in the TAG/apoB-100 ratio in VLDL when compared with non-carriers [<xref rid="B14" ref-type="bibr">14</xref>] and suggests that <italic>ANGPTL3</italic>-silenced cells display enhanced insulin sensitivity as VLDL1 particles dominate the VLDL profile in insulin-resistant states.</p>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <title>Silencing of <italic>ANGPTL3</italic></title>
          <p>IHH-cells were transduced with <italic>ANGPTL3</italic>-targeting or non-targeting shRNA (control). Cells were incubated in 5.5Â mM glucose with 100Â nM insulin (+/â) for 24Â h. RNA was extracted from cell lysates. (<bold>a</bold>) Expression of <italic>ANGPTL3</italic> (AU, arbitrary unit). (<bold>b</bold>) Secretion of ANGPTL3 (ng/mg).</p>
        </caption>
        <graphic xlink:href="bsr2014-0115i004"/>
      </fig>
      <fig id="F5" position="float">
        <label>Figure 5</label>
        <caption>
          <title>Secretion of VLDL from <italic>ANGPTL3</italic>-silenced and control IHH cells</title>
          <p><italic>ANGPTL3</italic>-silenced and control cells were incubated in media containing 5.5Â mM glucose and 100Â nM insulin (+/â). (<bold>a</bold>â<bold>c</bold>) Secretion of TAG, PL (Î¼g/mg) and apoB-100 (ng/mg). (<bold>d</bold>) Secretion of short-term apoB-100 (ng/mg). (<bold>e</bold>) The amount of TAG (ng) for each ng of apoB-100.</p>
        </caption>
        <graphic xlink:href="bsr2014-0115i005"/>
      </fig>
      <p>We then measured glucose uptake in control and silenced cells by utilizing a non-hydrolysable radiotracer, [<sup>3</sup>H]-labelled deoxy-<sc>D</sc>-glucose. Basal glucose uptake without insulin stimulus was increased by 50% in <italic>ANGPTL3</italic> silenced cells compared with control cells after 2Â h (<xref ref-type="fig" rid="F6">Figure 6</xref>a) and after 24Â h (<xref ref-type="fig" rid="F6">Figure 6</xref>b). Treatment with rosiglitazone improved hepatocyte glucose uptake by 40% in control cells (<xref ref-type="fig" rid="F6">Figure 6</xref>a). Acute insulin stimulus in the presence of 5.5Â mM glucose did not increase hepatocyte glucose uptake in control cells and significantly decreased glucose uptake in <italic>ANGPTL3</italic>-silenced cells after 2Â h (<xref ref-type="fig" rid="F6">Figure 6</xref>a) and 24Â h (<xref ref-type="fig" rid="F6">Figure 6</xref>b). When the glucose concentration was increased up to 20Â mM the inhibitory effect of insulin on glucose uptake was abolished (<xref ref-type="fig" rid="F6">Figure 6</xref>c). We conclude that the silencing of <italic>ANGPTL3</italic> results in increased glucose uptake comparable with rosiglitazone treatment in the absence of insulin stimulus and that insulin inhibits hepatocyte-specific glucose uptake in the presence of low glucose concentrations but not under high glucose concentration.</p>
      <fig id="F6" position="float">
        <label>Figure 6</label>
        <caption>
          <title>Hepatic glucose uptake in <italic>ANGPTL3</italic>-silenced and control cells</title>
          <p><italic>ANGPTL3</italic>-silenced and control cells were incubated in the presence of [<sup>3</sup>H] labelled deoxy-<sc>D</sc>-glucose. Radioactivity (CPM) was measured from the cell lysates. (<bold>a</bold>) Hepatic glucose uptake measured after 2Â h incubation period in media containing 5.5Â mM glucose (CPM/mg). Cells were incubated with 50Â Î¼M rosiglitazone or 100Â nM insulin (+/â). (<bold>b</bold>) Hepatic glucose uptake measured after 24Â h incubation period in media containing 5.5Â mM glucose and 100Â nM insulin (+/â) (CPM/mg). (<bold>c</bold>) Hepatic glucose uptake measured after 2Â h incubation period in media containing 20Â mM glucose and 100Â nM insulin (+/â) (CPM/mg).</p>
        </caption>
        <graphic xlink:href="bsr2014-0115i006"/>
      </fig>
      <p>We reasoned that the increased glucose uptake in <italic>ANGPTL3</italic>-silenced hepatocytes would cause elevation in glycogen and intracellular TAG levels and measured the intracellular TAG levels after 24Â h incubation period. We observed elevated intracellular TAG levels in <italic>ANGPTL3</italic>-silenced cells as compared with control cells (<xref ref-type="fig" rid="F7">Figure 7</xref>a). To test whether silencing of <italic>ANGPTL3</italic> affected hepatic fatty acid uptake we incubated control and <italic>ANGPTL3</italic>-silenced cells in media containing [<sup>14</sup>C]-labelled oleic acid bound to 0.5% BSA for 12Â h and measured the uptake of fatty acids and its conversion into intracellular TAG. There were no differences in fatty acid incorporation in intracellular TAG and the secretion rates of TAG between control and <italic>ANGPTL3</italic>-silenced cells (<xref ref-type="fig" rid="F7">Figure 7</xref>b).</p>
      <fig id="F7" position="float">
        <label>Figure 7</label>
        <caption>
          <title>Intracellular TAG and fatty acid uptake in <italic>ANGPTL3</italic>-silenced and control cells</title>
          <p>(<bold>a</bold>) Intracellular TAGs were measured in <italic>ANGPTL3</italic>-silenced and control cell lysates after 24Â h incubation with 5.5Â mM glucose and 100Â nM insulin (+/â). (<bold>b</bold>) <italic>ANGPTL3</italic>-silenced and control cells were incubated in media containing 5.5Â mM glucose, 0.375Â mM oleic acid complexed with 0.5% BSA and C<sup>14â</sup> labelled oleic acid for 12Â h. Radioactivity (DPM) in intracellular TAG and secreted TAG was measured (DPM/mg).</p>
        </caption>
        <graphic xlink:href="bsr2014-0115i007"/>
      </fig>
      <p>Finally we investigated whether silencing of <italic>ANGPTL3</italic> changes the expression of insulin responsive genes. QPCR demonstrated that there were no significant changes in gene expression levels of <italic>ANGPTL8</italic> or <italic>ANGPTL4</italic> between control and silenced cells (<xref ref-type="fig" rid="F8">Figure 8</xref>a). Insulin receptor <italic>IRS-2</italic>, <italic>GLUT2</italic> and <italic>PI3K</italic> (regulatory subunit p85) show a moderate (but non-significant) up-regulation in <italic>ANGPTL3</italic>-silenced cells in non-insulin conditions without any differences in <italic>IRS-1</italic> or PI3K inhibitor PTEN (phosphatase and tensin homologue deleted on chromosome 10) (<xref ref-type="fig" rid="F8">Figure 8</xref>b). Expression of <italic>PGC1Î±</italic> (peroxisome proliferator-activated receptor Î³ co-activator 1-Î±) and its downstream targets <italic>PEPCK</italic> (phosphoenolpyruvate carboxy-kinase) and <italic>TRB-3</italic> (tribbles homologue 3) were significantly down-regulated in <italic>ANGPTL3</italic>-silenced cells, whereas expression of <italic>PPARÎ±</italic> was significantly up-regulated in <italic>ANGPTL3</italic>-silenced cells (<xref ref-type="fig" rid="F8">Figure 8</xref>c). The mRNA levels of PPARÎ³ displayed a moderate down-regulation in <italic>ANGPTL3</italic>-silenced cells upon insulin stimulation (<xref ref-type="fig" rid="F8">Figure 8</xref>c). The expression of TGH (TAG hydrolase) and DGAT2 (diacylgylcerol acyltransferase 2) involved in VLDL assembly were up-regulated in <italic>ANGPTL3</italic>-silenced cells during insulin stimulus while the expression of inflammation marker TNFÎ± (tumour necrosis factor Î±) was significantly down-regulated in the silenced cells (<xref ref-type="fig" rid="F8">Figure 8</xref>d). There was no significant difference in IL-6 (interleukin-6) or HNF4Î± (hepatocyte nuclear factor Î±) expression (<xref ref-type="fig" rid="F8">Figure 8</xref>d). These data suggest a down-regulation of gluconeogenic genes and an increase in genes promoting TAG synthesis in <italic>ANGPTL3</italic>-silenced cells as compared with control.</p>
      <fig id="F8" position="float">
        <label>Figure 8</label>
        <caption>
          <title>Gene expression patterns in <italic>ANGPTL3</italic>-silenced and control IHH cells during non-insulin condition (Ins-) and insulin stimulation (Ins+)</title>
          <p>(<bold>aâd</bold>) <italic>ANGPTL3</italic>-silenced cells and control cells were incubated with 5.5Â mM glucose and 100Â nM insulin (+/â) for 24Â h followed by total RNA extraction from cell lysates, cDNA synthesis and q-PCR (AU, arbitrary unit).</p>
        </caption>
        <graphic xlink:href="bsr2014-0115i008"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Since ANGPTL3 is primarily expressed in the liver [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>] and affects TAG clearance [<xref rid="B5" ref-type="bibr">5</xref>â<xref rid="B9" ref-type="bibr">9</xref>] and possibly fatty acid release from adipose tissue [<xref rid="B25" ref-type="bibr">25</xref>] it is unclear how extracellular signals affect ANGPTL3 secretion rates and how silencing of <italic>ANGPTL3</italic> would affect glucose and lipid metabolism in the liver. We show that activation of PPARÎ³ by its agonist rosiglitazone, much like insulin, decreased the expression and secretion of ANGPTL3 accompanied by reduced secretion of TAG. The association of rosiglitazone and reduced VLDLâTAG secretion has been established <italic>inÂ vivo</italic> [<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>]. Down-regulation of <italic>ANGPTL3</italic> gene expression upon rosiglitazone treatment can also be found in microarray data of primary human hepatocytes [<xref rid="B28" ref-type="bibr">28</xref>] and is verified by our data including decreased dose-dependent protein secretion. The effect of insulin on <italic>ANGPTL3</italic> expression and secretion was shown in HepG2 cells [<xref rid="B29" ref-type="bibr">29</xref>] and also verified by our data. These findings indicate that <italic>ANGPTL3</italic> is a target gene for insulin and PPARÎ³ action and demonstrate that stimulation of PPARÎ³ by rosiglitazone, mediates or mimics insulin action with a concomitant reduction in ANGPTL3 and VLDL secretion.</p>
      <p>Insulin stimulation reduces the secretion of TAG-enriched VLDL1-type particles in the liver without affecting the basal secretion of the lipid-poor VLDL2-type particles [<xref rid="B16" ref-type="bibr">16</xref>]. This balance is disrupted in IR leading to increased secretion of VLDL1 and increased plasma lipid levels [<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>]. Interestingly a loss of function mutation in the <italic>ANGPTL3-</italic>gene results in decreased levels of all lipoprotein typesÂ in plasma [<xref rid="B14" ref-type="bibr">14</xref>] but whether the hypolipidaemic phenotype is caused by decreased hepatic VLDL secretion or due to enhanced TAG clearance in the peripheral tissue (or both) has not been verified clearly. The work by Musunuru et al. [<xref rid="B13" ref-type="bibr">13</xref>] suggested lower apoB-100 production rate in homozygous human carriers of ANGPTL3 loss of function mutations. Shimizugawa et al. [<xref rid="B9" ref-type="bibr">9</xref>] and Ando et al. [<xref rid="B30" ref-type="bibr">30</xref>] suggest that the low plasma lipid levels (especially TAGs) observed in ANGPTL3-deficient mice were likely caused by increased VLDLâTAG clearance via induced LPL activity rather than decreased VLDL secretion.</p>
      <p>We did not detect decreased apoB-secretion in <italic>ANGPTL3</italic>-silenced cells compared with control; however, silencing of <italic>ANGPTL3</italic> caused a major decrease in secreted TAG during insulin stimulation with a more subtle effect on apoB-100 secretion. This observation is in line with the analysis on VLDL particles isolated from plasma of <italic>ANGPTL3</italic>-deficient subjects showing a dramatic reduction in VLDL particle size and a 4.3-fold reduction in the TAG/apoB-100 ratio [<xref rid="B14" ref-type="bibr">14</xref>]. We demonstrate that a shift from the secretion of TAG-enriched VLDL1-type particles into the secretion of TAG poor VLDL2-type particles under insulin stimulus was more pronounced in ANGPTL3 silenced cells compared with control cells suggesting elevated insulin sensitivity. Higher insulin sensitivity in homozygous <italic>ANGPTL3</italic> loss-of-function carriers was demonstrated previously by Robciuc et al. [<xref rid="B14" ref-type="bibr">14</xref>] thus supporting our cell data. Additionally Inukai et al. [<xref rid="B31" ref-type="bibr">31</xref>] showed elevated ANGPTL3 expression in mice in both insulin-deficient and -resistant diabetic states. Therefore down-regulation of <italic>ANGPTL3</italic> might have a protective role against IR.</p>
      <p>Liver uptake accounts for about 30% disposal of plasma glucose [<xref rid="B32" ref-type="bibr">32</xref>]. Silencing of <italic>ANGPTL3</italic> resulted in 20â50% increase in glucose uptake compared with control cells and probably explaining glucose conversion into intracellular TAGs and their increased secretion in <italic>ANGPTL3</italic>-silenced cells under insulin-depleted conditions. Human data do not support an increased prevalence of hepatic steatosis in <italic>ANGPTL3</italic>-deficient subjects [<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B33" ref-type="bibr">33</xref>] suggesting that fluctuations in the availability of substrates, plasma glucose and insulin concentrations <italic>inÂ vivo</italic> as well as uptake of glucose and fatty acids by other tissues regulate hepatic glucose uptake and VLDL secretion and thereby preventing hepatic TAG accumulation in ANGPTL3-deficient individuals.</p>
      <p>Our data on VLDL secretion and glucose uptake suggests that both insulin and PPARÎ³ might mediate some of their functions via affecting the expression of <italic>ANGPTL3</italic>. Activation of PPARÎ³ decreases the transcription of insulin-responsive genes involved in the control of glucose production (gluconeogenesis) [<xref rid="B34" ref-type="bibr">34</xref>] and PPARÎ³ can directly activate GLUT2 transporter thus influencing hepatic glucose uptake [<xref rid="B35" ref-type="bibr">35</xref>] which can explain the increased short-term glucose uptake levels upon rosiglitazone treatment in the present study. We show that silencing of <italic>ANGPTL3</italic> resulted in significant down-regulation of transcription factor <italic>PGC1Î±</italic> expression and its downstream targets <italic>PEPCK</italic> and <italic>TRB3</italic> (tribbles homologue 3), a protein kinase acting as a negative inhibitor for Akt phosphorylation [<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>]. Elevation of <italic>PGC1Î±</italic> expression in liver has been linked to IR in several mouse and human studies [<xref rid="B37" ref-type="bibr">37</xref>â<xref rid="B39" ref-type="bibr">39</xref>] thus the down-regulation of <italic>PGC1Î±</italic> and its downstream targets as observed in <italic>ANGPTL3</italic>-silenced cells suggest decreased levels of gluconeogenesis and fatty acid oxidation, processes which display aberrant activation in insulin resistant states (See <xref ref-type="fig" rid="F9">Figure 9</xref> as a summary for the pathways).</p>
      <fig id="F9" position="float">
        <label>Figure 9</label>
        <caption>
          <title>Hypothetic model for ANGPTL3 function in a hepatocyte</title>
          <p>Silencing of ANGPTL3 enhances GLUT2-mediated glucose uptake, increases TAG synthesis and induces down-regulation of PGC1Î± and its downstream targets, including TRB3, hypothetically leading to enhanced Akt phosphorylation levels. Secretion of TAG-enriched VLDL-1-type particles is decreased upon insulin stimulus.</p>
        </caption>
        <graphic xlink:href="bsr2014-0115i009"/>
      </fig>
      <p>Insulin induces glucose uptake in insulin-responsive tissues (muscle, white adipose tissue) via GLUT4 but is not required for GLUT2-mediated glucose uptake by the liver [<xref rid="B39" ref-type="bibr">39</xref>]. In fact, insulin dose dependently decreases the expression of hepatocyte <italic>GLUT2</italic> during the first 6â12Â h of insulin stimulation <italic>inÂ vitro</italic> and <italic>inÂ vivo</italic>. The inhibitory effect of insulin on <italic>GLUT2</italic> expression is abolished after 24Â h despite continuous insulin stimulation and can also be reversed by high (10â20Â mM) glucose concentration [<xref rid="B21" ref-type="bibr">21</xref>]. Therefore hepatic glucose uptake is driven by extracellular glucose concentration and not directly due to the elevated insulin levels (in other words GLUT2 is not insulin dependent). Increased glucose uptake in <italic>ANGPTL3</italic>-silenced cells might be due to higher production rate of GLUT2 and/or increased plasma membrane translocation and activation of GLUT2. In conclusion, our results give insights into the mechanisms of <italic>ANGPTL3</italic>-silencing in hepatic lipid and glucose metabolism. Since humans with ANGPTL3-deficiency display hypolipidaemia and insulin sensitivity it might be beneficial to target <italic>ANGPTL3 i</italic>n the liver, the major site of <italic>ANGPTL3</italic> expression, to balance lipid and glucose homoeostasis and lower the risk of cardiometabolic disorders.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGEMENTS</title>
      <p>We thank Sari Nuutinen from the National Institute for Health and Welfare (Helsinki, Finland) for her technical assistance and Marius Robciuc from the National Institute for Health and Welfare for his previous work with lentiviral shRNA particles and ANGPTL3-protein.</p>
    </ack>
    <sec>
      <title>AUTHOR CONTRIBUTION</title>
      <p>Matti Jauhiainen and Christian Ehnholm supervised the study. Jarkko Soronen participated in study design and scientific discussion of the data. Pirkka-Pekka Laurila contributed to the scientific discussion of the data. Jari Metso contributed to the biochemical analysis of the experiments.</p>
    </sec>
    <sec>
      <title>FUNDING</title>
      <p>The study was financially supported by the <funding-source id="gs1">Academy of Finland</funding-source> [grant number <award-id rid="gs1">257545</award-id>], <funding-source id="gs2">Finnish Foundation for Cardiovascular Research</funding-source>, <funding-source id="gs3">Jenny and Antti Wihuri Foundation</funding-source>, <funding-source id="gs4">Finska LÃ¤karesÃ¤llskapet</funding-source>, <funding-source id="gs5">Magnus Ehrnrooth foundation</funding-source> and <funding-source id="gs6">Novo Nordisk Fonden</funding-source>.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Papadopoulos</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Aldrich</surname>
              <given-names>T. H.</given-names>
            </name>
            <name>
              <surname>Maisonpierre</surname>
              <given-names>P. C.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kovac</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Leidich</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Radziejewska</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Rafique</surname>
              <given-names>A.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering</article-title>
          <source>Nat. Struct. Biol.</source>
          <year>2003</year>
          <volume>10</volume>
          <fpage>38</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.1038/nsb880</pub-id>
          <?supplied-pmid 12469114?>
          <pub-id pub-id-type="pmid">12469114</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ono</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shimizugawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Shimamura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Noji-Sakikawa</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Koishi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated <italic>inÂ vivo</italic></article-title>
          <source>J. Biol. Chem</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>41804</fpage>
          <lpage>41809</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M302861200</pub-id>
          <?supplied-pmid 12909640?>
          <pub-id pub-id-type="pmid">12909640</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conklin</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Gilbertson</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Taft</surname>
              <given-names>D. W.</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>M. F.</given-names>
            </name>
            <name>
              <surname>Whitmore</surname>
              <given-names>T. E.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>D. L.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>K. M.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L. H.</given-names>
            </name>
            <name>
              <surname>Wattler</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nehls</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>K. B.</given-names>
            </name>
          </person-group>
          <article-title>Identification of a mammalian angiopoietin-related protein expressed specifically in liver</article-title>
          <source>Genomics</source>
          <year>1999</year>
          <volume>62</volume>
          <fpage>477</fpage>
          <lpage>482</lpage>
          <pub-id pub-id-type="doi">10.1006/geno.1999.6041</pub-id>
          <?supplied-pmid 10644446?>
          <pub-id pub-id-type="pmid">10644446</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Romeo</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Kozlitina</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Pennacchio</surname>
              <given-names>L. A.</given-names>
            </name>
            <name>
              <surname>Boerwinkle</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hobbs</surname>
              <given-names>H. H.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>J. C.</given-names>
            </name>
          </person-group>
          <article-title>Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans</article-title>
          <source>J. Clin. Invest.</source>
          <year>2009</year>
          <volume>119</volume>
          <fpage>70</fpage>
          <lpage>79</lpage>
          <?supplied-pmid 19075393?>
          <pub-id pub-id-type="pmid">19075393</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Afroza</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Rader</surname>
              <given-names>D. J.</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases</article-title>
          <source>J. Biol. Chem.</source>
          <year>2010</year>
          <volume>285</volume>
          <fpage>27561</fpage>
          <lpage>27570</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M110.144279</pub-id>
          <?supplied-pmid 20581395?>
          <pub-id pub-id-type="pmid">20581395</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>E. C.</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Gololobov</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>X. C.</given-names>
            </name>
            <name>
              <surname>Gay</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wilganowski</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>L. L.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL)</article-title>
          <source>J. Biol. Chem.</source>
          <year>2009</year>
          <volume>284</volume>
          <fpage>13735</fpage>
          <lpage>13745</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M807899200</pub-id>
          <?supplied-pmid 19318355?>
          <pub-id pub-id-type="pmid">19318355</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shan</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>X. C.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sturgis</surname>
              <given-names>L. T.</given-names>
            </name>
            <name>
              <surname>Miranda</surname>
              <given-names>M. L.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Q.</given-names>
            </name>
          </person-group>
          <article-title>The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms</article-title>
          <source>J. Biol. Chem.</source>
          <year>2009</year>
          <volume>284</volume>
          <fpage>1419</fpage>
          <lpage>1424</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M808477200</pub-id>
          <?supplied-pmid 19028676?>
          <pub-id pub-id-type="pmid">19028676</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koishi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shimamura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yasumo</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Horikoshi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Angptl3 regulates lipid metabolism in mice</article-title>
          <source>Nat. Genet.</source>
          <year>2002</year>
          <volume>30</volume>
          <fpage>151</fpage>
          <lpage>157</lpage>
          <pub-id pub-id-type="doi">10.1038/ng814</pub-id>
          <?supplied-pmid 11788823?>
          <pub-id pub-id-type="pmid">11788823</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimizugawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shimamura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Koishi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ueda</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Inaba</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Minekura</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kohama</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase</article-title>
          <source>J. Biol. Chem.</source>
          <year>2002</year>
          <volume>277</volume>
          <fpage>33742</fpage>
          <lpage>33748</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M203215200</pub-id>
          <?supplied-pmid 12097324?>
          <pub-id pub-id-type="pmid">12097324</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kathiresan</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Melander</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Guiducci</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Surti</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Burtt</surname>
              <given-names>N. P.</given-names>
            </name>
            <name>
              <surname>Rieder</surname>
              <given-names>M. J.</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>G. M.</given-names>
            </name>
            <name>
              <surname>Roos</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Voight</surname>
              <given-names>B. F.</given-names>
            </name>
            <name>
              <surname>Havulinna</surname>
              <given-names>A. S.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans</article-title>
          <source>Nat. Genet.</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>189</fpage>
          <lpage>197</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.75</pub-id>
          <?supplied-pmid 18193044?>
          <pub-id pub-id-type="pmid">18193044</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teslovich</surname>
              <given-names>T. M.</given-names>
            </name>
            <name>
              <surname>Musunuru</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>A. V.</given-names>
            </name>
            <name>
              <surname>Edmondson</surname>
              <given-names>A. C.</given-names>
            </name>
            <name>
              <surname>Stylianou</surname>
              <given-names>I. M.</given-names>
            </name>
            <name>
              <surname>Koseki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pirruccello</surname>
              <given-names>J. P.</given-names>
            </name>
            <name>
              <surname>Ripatti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chasman</surname>
              <given-names>D. I.</given-names>
            </name>
            <name>
              <surname>Willer</surname>
              <given-names>C. J.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biological, clinical and population relevance of 95 loci for blood lipids</article-title>
          <source>Nature</source>
          <year>2010</year>
          <volume>466</volume>
          <fpage>707</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="doi">10.1038/nature09270</pub-id>
          <?supplied-pmid 20686565?>
          <pub-id pub-id-type="pmid">20686565</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willer</surname>
              <given-names>C. J.</given-names>
            </name>
            <name>
              <surname>Sanna</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>A. U.</given-names>
            </name>
            <name>
              <surname>Scuteri</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bonnycastle</surname>
              <given-names>L. L.</given-names>
            </name>
            <name>
              <surname>Clarke</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Heath</surname>
              <given-names>S. C.</given-names>
            </name>
            <name>
              <surname>Timpson</surname>
              <given-names>N. J.</given-names>
            </name>
            <name>
              <surname>Najjar</surname>
              <given-names>S. S.</given-names>
            </name>
            <name>
              <surname>Stringham</surname>
              <given-names>H. M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Newly identified loci that influence lipid concentrations and risk of coronary artery disease</article-title>
          <source>Nat. Genet.</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>161</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.76</pub-id>
          <?supplied-pmid 18193043?>
          <pub-id pub-id-type="pmid">18193043</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Musunuru</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Pirruccello</surname>
              <given-names>J. P.</given-names>
            </name>
            <name>
              <surname>Do</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Peloso</surname>
              <given-names>G. M.</given-names>
            </name>
            <name>
              <surname>Guiducci</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Sougnez</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Garimella</surname>
              <given-names>K. V.</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Abreu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Barry</surname>
              <given-names>A. J.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2010</year>
          <volume>363</volume>
          <fpage>2220</fpage>
          <lpage>2227</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1002926</pub-id>
          <?supplied-pmid 20942659?>
          <pub-id pub-id-type="pmid">20942659</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robciuc</surname>
              <given-names>M. R.</given-names>
            </name>
            <name>
              <surname>Maranghi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lahikainen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rader</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bensadoun</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>ÃÃ¶rni</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Metso</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Minicocci</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Ciociola</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ceci</surname>
              <given-names>F.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ANGPTL3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids</article-title>
          <source>Arterioscler. Thromb. Vasc. Biol.</source>
          <year>2013</year>
          <volume>33</volume>
          <fpage>1706</fpage>
          <lpage>1713</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.113.301397</pub-id>
          <?supplied-pmid 23661675?>
          <pub-id pub-id-type="pmid">23661675</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minicocci</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Montali</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Robciuc</surname>
              <given-names>M. R.</given-names>
            </name>
            <name>
              <surname>Quagliarini</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Censi</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Labbadia</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization</article-title>
          <source>J. Clin. Endocrinol. Metab.</source>
          <year>2012</year>
          <volume>97</volume>
          <fpage>E1266</fpage>
          <lpage>E1275</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2012-1298</pub-id>
          <?supplied-pmid 22659251?>
          <pub-id pub-id-type="pmid">22659251</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>MalmstrÃ¶m</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Packard</surname>
              <given-names>C. J.</given-names>
            </name>
            <name>
              <surname>Caslake</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bedford</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Yki-JÃ¤rvinen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Shepherd</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Taskinen</surname>
              <given-names>M. R.</given-names>
            </name>
          </person-group>
          <article-title>Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM</article-title>
          <source>Diabetologia</source>
          <year>1997</year>
          <volume>40</volume>
          <fpage>454</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="doi">10.1007/s001250050700</pub-id>
          <?supplied-pmid 9112023?>
          <pub-id pub-id-type="pmid">9112023</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garvey</surname>
              <given-names>W. T.</given-names>
            </name>
            <name>
              <surname>Kwon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Shaughnessy</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Hutto</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Effects of insulin resistance and typeÂ 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance</article-title>
          <source>Diabetes</source>
          <year>2003</year>
          <volume>52</volume>
          <fpage>453</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.52.2.453</pub-id>
          <?supplied-pmid 12540621?>
          <pub-id pub-id-type="pmid">12540621</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Jiao</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Nie</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice</article-title>
          <source>J. Clin. Invest.</source>
          <year>2010</year>
          <volume>120</volume>
          <fpage>3901</fpage>
          <lpage>3911</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI43250</pub-id>
          <?supplied-pmid 20921625?>
          <pub-id pub-id-type="pmid">20921625</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Okar</surname>
              <given-names>D. A.</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>A. J.</given-names>
            </name>
          </person-group>
          <article-title>Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes</article-title>
          <source>Curr. Drug Targets Immune Endocr. Metabol Disord.</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>51</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="doi">10.2174/1568008053174769</pub-id>
          <?supplied-pmid 15777204?>
          <pub-id pub-id-type="pmid">15777204</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chirieac</surname>
              <given-names>D. V.</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>N. O.</given-names>
            </name>
            <name>
              <surname>Sparks</surname>
              <given-names>C. E.</given-names>
            </name>
            <name>
              <surname>Sparks</surname>
              <given-names>J. D.</given-names>
            </name>
          </person-group>
          <article-title>PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1â/â mice</article-title>
          <source>Am. J. Physiol. Gastrointest. Liver Physiol.</source>
          <year>2006</year>
          <volume>291</volume>
          <fpage>G382</fpage>
          <lpage>G388</lpage>
          <pub-id pub-id-type="doi">10.1152/ajpgi.00472.2005</pub-id>
          <?supplied-pmid 16798720?>
          <pub-id pub-id-type="pmid">16798720</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Postic</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Burcelin</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Rencurel</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Pegorier</surname>
              <given-names>J. P.</given-names>
            </name>
            <name>
              <surname>Loizeau</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Girard</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Leturque</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Evidence for a transient inhibitory effect of insulin on GLUT2 expression in the liver: studies <italic>inÂ vivo</italic> and <italic>inÂ vitro</italic></article-title>
          <source>Biochem. J.</source>
          <year>1993</year>
          <volume>293</volume>
          <fpage>119</fpage>
          <lpage>124</lpage>
          <?supplied-pmid 8328952?>
          <pub-id pub-id-type="pmid">8328952</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robciuc</surname>
              <given-names>M. R.</given-names>
            </name>
            <name>
              <surname>Tahvanainen</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Jauhiainen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ehnholm</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample</article-title>
          <source>J. Lipid Res.</source>
          <year>2010</year>
          <volume>51</volume>
          <fpage>824</fpage>
          <lpage>831</lpage>
          <pub-id pub-id-type="doi">10.1194/jlr.M002618</pub-id>
          <?supplied-pmid 19826106?>
          <pub-id pub-id-type="pmid">19826106</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adiels</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Westerbacka</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Soro-Paavonen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>HÃ¤kkinen</surname>
              <given-names>A. M.</given-names>
            </name>
            <name>
              <surname>Vehkavaara</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Caslake</surname>
              <given-names>M. J.</given-names>
            </name>
            <name>
              <surname>Packard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Olofsson</surname>
              <given-names>S. O.</given-names>
            </name>
            <name>
              <surname>Yki-JÃ¤rvinen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Taskinen</surname>
              <given-names>M. R.</given-names>
            </name>
            <name>
              <surname>BorÃ©n</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance</article-title>
          <source>Diabetologia</source>
          <year>2007</year>
          <volume>50</volume>
          <fpage>2356</fpage>
          <lpage>2365</lpage>
          <pub-id pub-id-type="doi">10.1007/s00125-007-0790-1</pub-id>
          <?supplied-pmid 17849096?>
          <pub-id pub-id-type="pmid">17849096</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rother</surname>
              <given-names>K. I.</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Caruso</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Beguinot</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Formisano</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Accili</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes</article-title>
          <source>J. Biol. Chem.</source>
          <year>1998</year>
          <volume>273</volume>
          <fpage>17491</fpage>
          <lpage>17497</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.273.28.17491</pub-id>
          <?supplied-pmid 9651339?>
          <pub-id pub-id-type="pmid">9651339</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimamura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Koishi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Makishima</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shimomura</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <year>2003</year>
          <volume>301</volume>
          <fpage>604</fpage>
          <lpage>609</lpage>
          <pub-id pub-id-type="doi">10.1016/S0006-291X(02)03058-9</pub-id>
          <?supplied-pmid 12565906?>
          <pub-id pub-id-type="pmid">12565906</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carpentier</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Taghibiglou</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Szeto</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Van Iderstine</surname>
              <given-names>S. C.</given-names>
            </name>
            <name>
              <surname>Uffelman</surname>
              <given-names>K. D.</given-names>
            </name>
            <name>
              <surname>Buckingham</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Adeli</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>G. F.</given-names>
            </name>
          </person-group>
          <article-title>Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster</article-title>
          <source>J. Biol. Chem.</source>
          <year>2002</year>
          <volume>277</volume>
          <fpage>28795</fpage>
          <lpage>28802</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M204568200</pub-id>
          <?supplied-pmid 12048212?>
          <pub-id pub-id-type="pmid">12048212</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brackenridge</surname>
              <given-names>A. L.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Jefferson</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Stolinski</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shojaee-Moradie</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Hovorka</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Umpleby</surname>
              <given-names>A. M.</given-names>
            </name>
            <name>
              <surname>Russell-Jones</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with TypeÂ 2 diabetes and normal lipids</article-title>
          <source>Diabet. Med.</source>
          <year>2009</year>
          <volume>26</volume>
          <fpage>532</fpage>
          <lpage>539</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1464-5491.2009.02729.x</pub-id>
          <?supplied-pmid 19646194?>
          <pub-id pub-id-type="pmid">19646194</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rogue</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Renaud</surname>
              <given-names>M. P.</given-names>
            </name>
            <name>
              <surname>Claude</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Guillouzo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Spire</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Comparative gene expression profiles induced by PPARÎ³ and PPARÎ±/Î³ agonists in rat hepatocytes</article-title>
          <source>Toxicol. Appl. Pharmacol.</source>
          <year>2011</year>
          <volume>254</volume>
          <fpage>18</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1016/j.taap.2011.04.005</pub-id>
          <?supplied-pmid 21515302?>
          <pub-id pub-id-type="pmid">21515302</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimamura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Koishi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Yasumo</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Shimomura</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Leptin and insulin down-regulate angiopoietin-like protein 3,a plasma triglyceride-increasing factor</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <year>2004</year>
          <volume>322</volume>
          <fpage>1080</fpage>
          <lpage>1085</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbrc.2004.08.024</pub-id>
          <?supplied-pmid 15336575?>
          <pub-id pub-id-type="pmid">15336575</pub-id>
        </element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ando</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Shimizugawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Takeshita</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shimamura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Koishi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice</article-title>
          <source>J. Lipid. Res.</source>
          <year>2003</year>
          <volume>44</volume>
          <fpage>1216</fpage>
          <lpage>1223</lpage>
          <pub-id pub-id-type="doi">10.1194/jlr.M300031-JLR200</pub-id>
          <?supplied-pmid 12671033?>
          <pub-id pub-id-type="pmid">12671033</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inukai</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nakashima</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kurihara</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Awata</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Katagiri</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Oka</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Katayama</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <year>2004</year>
          <volume>317</volume>
          <fpage>1075</fpage>
          <lpage>1079</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbrc.2004.03.151</pub-id>
          <?supplied-pmid 15094378?>
          <pub-id pub-id-type="pmid">15094378</pub-id>
        </element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>M. C.</given-names>
            </name>
            <name>
              <surname>Coate</surname>
              <given-names>K. C.</given-names>
            </name>
            <name>
              <surname>Winnick</surname>
              <given-names>J. J.</given-names>
            </name>
            <name>
              <surname>An</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Cherrington</surname>
              <given-names>A. D.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of hepatic glucose uptake and storage <italic>inÂ vivo</italic></article-title>
          <source>Adv. Nutr.</source>
          <year>2012</year>
          <volume>3</volume>
          <fpage>286</fpage>
          <lpage>294</lpage>
          <pub-id pub-id-type="doi">10.3945/an.112.002089</pub-id>
          <?supplied-pmid 22585902?>
          <pub-id pub-id-type="pmid">22585902</pub-id>
        </element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minicocci</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Santini</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cantisani</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Stitziel</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Kathiresan</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Arroyo</surname>
              <given-names>J. A.</given-names>
            </name>
            <name>
              <surname>MartÃ­</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pisciotta</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Noto</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>CefalÃ¹</surname>
              <given-names>A. B.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis</article-title>
          <source>J. Lipid Res.</source>
          <year>2013</year>
          <volume>54</volume>
          <fpage>3481</fpage>
          <lpage>3490</lpage>
          <pub-id pub-id-type="doi">10.1194/jlr.P039875</pub-id>
          <?supplied-pmid 24058201?>
          <pub-id pub-id-type="pmid">24058201</pub-id>
        </element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Way</surname>
              <given-names>J. M.</given-names>
            </name>
            <name>
              <surname>Harrington</surname>
              <given-names>W. W.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>K. K.</given-names>
            </name>
            <name>
              <surname>Gottschalk</surname>
              <given-names>W. K.</given-names>
            </name>
            <name>
              <surname>Sundseth</surname>
              <given-names>S. S.</given-names>
            </name>
            <name>
              <surname>Mansfield</surname>
              <given-names>T. A.</given-names>
            </name>
            <name>
              <surname>Ramachandran</surname>
              <given-names>R. K.</given-names>
            </name>
            <name>
              <surname>Willson</surname>
              <given-names>T. M.</given-names>
            </name>
            <name>
              <surname>Kliewer</surname>
              <given-names>S. A.</given-names>
            </name>
          </person-group>
          <article-title>Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues</article-title>
          <source>Endocrinology</source>
          <year>2001</year>
          <volume>142</volume>
          <fpage>1269</fpage>
          <lpage>1277</lpage>
          <?supplied-pmid 11181544?>
          <pub-id pub-id-type="pmid">11181544</pub-id>
        </element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>H. I.</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>Y. H.</given-names>
            </name>
          </person-group>
          <article-title>Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells</article-title>
          <source>Diabetes</source>
          <year>2004</year>
          <volume>53</volume>
          <fpage>S60</fpage>
          <lpage>S65</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.53.2007.S60</pub-id>
          <?supplied-pmid 14749267?>
          <pub-id pub-id-type="pmid">14749267</pub-id>
        </element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoon</surname>
              <given-names>J. C.</given-names>
            </name>
            <name>
              <surname>Puigserver</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Donovan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Rhee</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Adelmant</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Stafford</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>C. R.</given-names>
            </name>
            <name>
              <surname>Granner</surname>
              <given-names>D. K.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>413</volume>
          <fpage>131</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="doi">10.1038/35093050</pub-id>
          <?supplied-pmid 11557972?>
          <pub-id pub-id-type="pmid">11557972</pub-id>
        </element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koo</surname>
              <given-names>S. H.</given-names>
            </name>
            <name>
              <surname>Satoh</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Herzig</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C. H.</given-names>
            </name>
            <name>
              <surname>Hedrick</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>R. M.</given-names>
            </name>
            <name>
              <surname>Olefsky</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Montminy</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3</article-title>
          <source>Nat. Med.</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>530</fpage>
          <lpage>534</lpage>
          <pub-id pub-id-type="doi">10.1038/nm1044</pub-id>
          <?supplied-pmid 15107844?>
          <pub-id pub-id-type="pmid">15107844</pub-id>
        </element-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Finck</surname>
              <given-names>B. N.</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>D. P.</given-names>
            </name>
          </person-group>
          <article-title>PGC-1 coactivators: inducible regulators of energy metabolism in health and disease</article-title>
          <source>J. Clin. Invest.</source>
          <year>2006</year>
          <volume>116</volume>
          <fpage>615</fpage>
          <lpage>622</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI27794</pub-id>
          <?supplied-pmid 16511594?>
          <pub-id pub-id-type="pmid">16511594</pub-id>
        </element-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olson</surname>
              <given-names>A. L.</given-names>
            </name>
            <name>
              <surname>Pessin</surname>
              <given-names>J. E.</given-names>
            </name>
          </person-group>
          <article-title>Structure, function, and regulation of the mammalian facilitative glucose transporter gene family</article-title>
          <source>Annu. Rev. Nutr.</source>
          <year>1996</year>
          <volume>16</volume>
          <fpage>235</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.nu.16.070196.001315</pub-id>
          <?supplied-pmid 8839927?>
          <pub-id pub-id-type="pmid">8839927</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>